News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
29
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4024
|
|
Created
|
08/25/00
|
Type
|
Free
|
| Moderators | |||
AmStem Corporation (AMST)
formerly Stem Cell Therapy International, Inc. (SCII)
Warning!!!
iBox may have incorrect data due to major changes in company status.
Will update ASAP.
Keep in mind that moderators may or may not have a position in said stock.
Being a moderator isn't a sign of endorsement.
AmStem Corporation
Formerly known as Stem Cell Therapy International, Inc.
The company appears to be a shell that is now 60% owned by Histostem http://www.histostem.co.kr/english/english_1.htm
The hope for shareholders is that Histostem brings product to the US market via this shell.
CIK: 0001360479
Histostem Cord Blood Storage
Exciting New Treatments
Clinical Trials: Stem Cell Treatments for Incurable Disease
Histostem Ltd. of South Korea, has enjoyed a unique position in the world of stem cell research for a number of years. In February 2007, they received approval from the Korean FDA to use stem cells as a "surgical technique" to treat virtually any emergency condition.
Buoyed by this unprecedented regulatory support, Dr. Hoon Han of Histostem has partnered with leading researchers at the finest hospitals and universities in Korea, to study the treatment of intractable disease using non-controversial stem cells derived from umbilical cord blood. While using his patented techniques to prepare and treat patients, Dr. Han and his research team have compiled a significant body of research data that is unique in the world.
The initial data shows some exciting successes, and AmStem will be validating these early results with controlled clinical trials designed to the highest international (ICH) standards.
Management Team: http://www.amsteminc.com/about-amstem/management-team
Dr. Han Hoon, M.D., PhD
President of Histostem Korea.
Internationally recognized scientist in stem cell and regenerative treatment
Histostem Lab
Patents Registered & Pending by Histostem http://amsteminc.com/technology/patents
Press Releases:
http://amsteminc.com/investor-relations/press-releases
http://finance.yahoo.com/q/h?s=AMST.PK
Histostem Press Releases:
07/07/05 South Korean medical firm offers stem cell treatment to foreigners
03/22/05 AFP 'Seoul blood bank freezes assets for breakthrough cell therapy'
11/26/04 The Korea Times 'Korean Scientists Succeeded in Stem Cell Therapy'
Filings:
http://sec.gov/cgi-bin/browse-edgar?CIK=0001360479&action=getcompany
Fiscal year ends March 31
Transfer Agent:
Standard Transter & Trust Co., Inc.
2980 S Rainbow Blvd.
Suite 120
Las Vegas, NV89146
Office (702) 987-1328
Fax (866) 801-4192
Share Structure:
Coming
Investor Relations:
http://www.hawkassociates.com/clients/
Hawk Associates
Tom Fox
(305) 451-1888
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
